Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.57 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863827 | 0.92 | PDCD1 (0.53) | PDCD1CD274KMT2AMEN1NPC1 | |
| SCHEMBL11966930 | 0.86 | LTB4R2 (0.50) | PDCD1CD274KMT2AMEN1NPC1 | |
| SCHEMBL29655972 | 0.83 | TRPA1 (0.46) | PDCD1CD274KMT2AMEN1FFAR1 | |
| SCHEMBL7934930 | 0.83 | TRPA1 (0.46) | PDCD1CD274KMT2AMEN1FFAR1 | |
| SCHEMBL7951583 | 0.82 | PDCD1 (0.61) | PDCD1CD274KMT2APDK2HTR7 | |
| SCHEMBL10702715 | 0.82 | PDCD1 (0.52) | PDCD1CD274KMT2AMEN1NPC1 | |
| SCHEMBL2492790 | 0.82 | PDCD1 (0.52) | PDCD1CD274KMT2AMEN1NPC1 | |
| SCHEMBL30826353 | 0.81 | PDCD1 (0.65) | PDCD1CD274KMT2APDK2HTR7 | |
| SCHEMBL117091 | 0.81 | PDCD1 (0.65) | PDCD1CD274KMT2APDK2HTR7 | |
| SCHEMBL2450681 | 0.81 | HTR7 (0.47) | PDCD1CD274KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291511-B1 | Biarylalkanoic acids as cell adhesion inhibitors | MERCK & CO., INC. | 2001-09-18 | — | — | US | claimed |
| EP-4310067-A1 | METHOD FOR PRODUCING ORGANIC METAL NUCLEOPHILIC AGENT AND REACTION METHOD USING ORGANIC METAL NUCLEOPHILIC AGENT | National University Corporation Hokkaido University (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| WO-2022196796-A1 | METHOD FOR PRODUCING ORGANIC METAL NUCLEOPHILIC AGENT AND REACTION METHOD USING ORGANIC METAL NUCLEOPHILIC AGENT | 国立大学法人北海道大学 | 2022-09-22 | — | — | WO | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-7968727-B2 | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists | LEK PHARMACEUTICALS, D.D. (SI) | 2011-06-28 | — | — | US | disclosed |
| WO-2006103068-A1 | A SYNTHESIS OF 4-BROMOMETHYL-2'-FORMYLBIPHENYL AND 4-BROMOMETHYL-2'- HYDROXYMETHYLBIPHENYL AND ITS USE IN PREPARATION OF ANGIOTENSIN II ANTAGONISTS | LEK PHARMACEUTICALS D.D. (SI) | 2006-10-05 | — | — | WO | disclosed |
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002030897-A2 | COMPOSITIONS AND METHODS FOR REGULATING THE NERVOUS SYSTEM | FILLION GILLES (FR) | 2002-04-18 | — | — | WO | disclosed |
| US-6100252-A | SPECIFIED COMPOUNDS INCLUDING METHYL 2-BUTYL-1-((2'-(2-OXO-3H-1,2,3,5-OXATHIADIAZOL-4-YL)BIPHENYL) METHYL)-BENZIMIDAZOLE-7-CARBOXYLATE; USE TO TREAT CIRCULATORY DISEASES SUCH AS HYPERTENSIVE DISEASES AND HEART DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-5883111-A | STRONG AND LONG-LASTING ACTION BY ORAL ADMINISTRATION; HYPOTENSIVE AGENTS; CARDIOTONIC AGENTS; ALZHEIMER'S DISEASE; | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5736555-A | HYPOTENSIVE AGENTS; FDA ORANGE BOOK LISTED PATENT FOR AZILSARTAN MEDOXOMIL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-07 | — | — | US | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-3968147-A | COORDINATION CATALYST | MONSANTO COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HPD, TALDO1, OGG1 | PDCD1 590/4885CD274 2516/4885KMT2A 1249/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | PDCD1 62/4885CD274 116/4885KMT2A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.